|
Aug 28
|
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
|
|
Jun 20
|
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
|
|
Jun 19
|
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
|
|
Jun 18
|
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
|
|
Apr 24
|
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
|
|
Jan 15
|
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
|
|
Dec 4
|
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA
|
|
Nov 29
|
Theralase Release's 3Q2023 Interim Financial Statements
|
|
Nov 29
|
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
|
|
Sep 21
|
Theralase(R) Grants Stock Options
|
|
Sep 7
|
Theralase(R) Closes Private Placement Equity Financing
|
|
Jun 30
|
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
|
|
May 24
|
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
|